Biomarkers and Targeted Therapy in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) constitutes 90% of pancreatic cancers. PDAC is a complex and devastating disease with only 1%–3% survival rate in five years after the second stage. Treatment of PDAC is complicated due to the tumor microenvironment, changing cell behaviors to the mesenchymal...

Descripción completa

Detalles Bibliográficos
Autores principales: Karandish, Fataneh, Mallik, Sanku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847554/
https://www.ncbi.nlm.nih.gov/pubmed/27147897
http://dx.doi.org/10.4137/BiC.s34414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847554/
https://www.ncbi.nlm.nih.gov/pubmed/27147897
http://dx.doi.org/10.4137/BiC.s34414

Ejemplares similares